Roche and Nurix Therapeutics Partner to Advance BTK Degrader Bexobrutideg
Roche has entered into an exclusive licensing and collaboration agreement with Nurix Therapeutics to jointly develop and commercialize bexobrutideg (NX-5948), Nurix’s investigational Bruton’s Tyrosine Kinase (BTK) degrader. Through this partnership, both companies will advance a broad clinical development program across B-cell malignancies, immunology, and neurology. The addition of bexobrutideg further strengthens Roche’s hematology franchise while expanding opportunities to address diseases in immunology and neurology.
Despite significant progress with BTK inhibitors and other therapeuti...
